A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.

Trial Profile

A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Simvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms EASEGO
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 24 Oct 2009 Results of an economic analysis were presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top